Drug intelligence / Profile preview

OMK-I

Development stage: Preclinical
Lead developer: Allegro
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Injection

Overview

OMK-I is an artificial meniscus cartilage scaffold developed by Allegro for the treatment of meniscus injuries. Formulated as an injectable gel, it serves as a structural matrix to support the repair and regeneration of damaged meniscus tissue. The program is currently in the preclinical stage of development, aiming to offer a minimally invasive alternative to traditional surgical meniscus repair by providing a structural environment that facilitates natural healing processes.

Beyond the preview

Go deeper on OMK-I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMK-I.

Explore the full profile